The SourceCheck 4Pi ionization chamber shows an additional dependence with the air density which is clearly linear. The air density dependence of the three analyzed chambers can be represented by the same function, showing that there is not a significative variability between them regarding this dependence. Acknowledgement: We are grateful for financial and material support from PTW. GammaMed HDR Plus, 2 GammaMed PDR Plus, one VS2000 and one Co0.A86 were audited. A virtual line source was generated within each centre's planning system using 11 dwell positions, 5 mm apart, and dwell times calculated to deliver 10 Gy 20 mm away from the midpoint of the central dwell. This is equivalent to Point A of the Manchester system. The line source was delivered in a Solid Water TM phantom [Aird et al, EP-1924. Radiat Oncol April 2014111(S1):752] and absorbed dose measured with both an ion chamber (PTW TW30012) and alanine. Charge was measured in 3 positions (120° apart, 20 mm from source) and averaged to reduce source geometric variations. A further measurement point was created at 50 mm from the source to determine absorbed dose at the equivalent of Point B of the Manchester system. Results: Ion chamber measurements for all centres showed a mean difference (±sd) of +0.9% (±1.2) and +1.3% (±1.4) when compared to the centres' calculated dose at 20 mm and 50 mm, respectively. The mean alanine measurement at Point A was +2.0% (±1.5). There was a noticeable difference between source types, see Table 1 . Furthermore, there were large discrepancies in dose measured in each of the three holes due to positional variation of the source within the catheter and anisotropy of the source, ranging from +0.4 to 4.9% maximum difference between two holes.
Purpose/Objective: A multicentre audit to evaluate HDR and PDR brachytherapy using alanine and ion chamber absolute dosimetry. This is the first National UK audit of its type, performed for both INTERLACE and non-INTERLACE study centres treating gynaecological tumours using brachytherapy. Materials and Methods: 45 UK brachytherapy centres were visited from October 2013 to August 2014. A variety of source types including: 7 Flexisource, 23 mHDR-v2, 11 GammaMed HDR Plus, 2 GammaMed PDR Plus, one VS2000 and one Co0.A86 were audited. A virtual line source was generated within each centre's planning system using 11 dwell positions, 5 mm apart, and dwell times calculated to deliver 10 Gy 20 mm away from the midpoint of the central dwell. This is equivalent to Point A of the Manchester system. The line source was delivered in a Solid Water TM phantom [Aird et al, EP-1924 . Radiat Oncol April 2014 111(S1) :752] and absorbed dose measured with both an ion chamber (PTW TW30012) and alanine. Charge was measured in 3 positions (120° apart, 20 mm from source) and averaged to reduce source geometric variations. A further measurement point was created at 50 mm from the source to determine absorbed dose at the equivalent of Point B of the Manchester system. Results: Ion chamber measurements for all centres showed a mean difference (±sd) of +0.9% (±1.2) and +1.3% (±1.4) when compared to the centres' calculated dose at 20 mm and 50 mm, respectively. The mean alanine measurement at Point A was +2.0% (±1.5). There was a noticeable difference between source types, see Table 1 . Furthermore, there were large discrepancies in dose measured in each of the three holes due to positional variation of the source within the catheter and anisotropy of the source, ranging from +0.4 to 4.9% maximum difference between two holes.
Conclusions:
A comprehensive audit of absolute dose to water from a line brachytherapy source was performed showing all centres could deliver the prescribed dose to within 5%. There was a significant positional variation of the source detected in the measurements and differences were also seen between the source types. 
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Materials and Methods:
A novel QA device, named 'magic phantom' (MPh), has been developed which will allow for the pre-treatment delivery verification of plans in HDR brachytherapy. It assesses source dwell positions and times, and potential differences in planned and calculated delivered dose. The MPh system comprises of a two-dimensional array of 121 silicon diode detectors with low noise and fast readout electronics, a measurement and analysis software toolkit, and a portable Perspex phantom. The detector array is inserted within the phantom, between two rows of HDR brachytherapy catheters, allowing for the verification of treatment plans with up to 20 catheters. A 20 catheter plan was generated to simulate a nonspecific patient treatment scenario. This was delivered to the MPh and using a developed four-dimensional source tracking algorithm, the treatment dwell position and times were determined in post-processing. A new metric, the 'positiontime gamma index', was developed to quantify the quality of the measured delivery when compared to the treatment plan. The original plan dwell positions and timing patterns were then modified to simulate multiple afterloader delivery errors. These changes were not disclosed to the investigators, and were to be determined by the MPh measurement. Results: The device was shown to determine dwell times as short as 0.06 s and dwell positions separated by 1 mm. For the original plan, the MPh measured all dwell positions and times, with the majority found to be within 0.93 mm and 0.25 s from the planned, respectively. By assessing the altered plan and comparing it to the unmodified, the use of the position-time gamma index showed that all amendments made could be easily detected. Seen in Fig. 1, all 11 
